Drug Trial Radar · NCT00003934
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Last checked: Nov 20, 2026Latest source record: Jun 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Jun 1999
Primary completion
Nov 2006
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia.
Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Promyelocytic Leukemia (M3)
- Childhood Acute Promyelocytic Leukemia (M3)
- Untreated Adult Acute Myeloid Leukemia
- Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
tretinoinDrug
Given orally
daunorubicin hydrochlorideDrug
Given IV
cytarabineDrug
Given IV
mercaptopurineDrug
Given IV
methotrexateDrug
Given IV
arsenic trioxideDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response ratesTime frame: Up to 10 years
- Distributions of event-free survivalTime frame: Up to 10 years
- Disease-free survivalTime frame: Time from the date of the maintenance randomization to relapse or death, assessed up to 10 years
- SurvivalTime frame: Up to 10 years
- Toxicities for the various therapies graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0Time frame: Up to 30 days after last dose of study treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer and Leukemia Group B
Chicago, Illinois
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.